BioSpace News Archive

Chugai Pharmaceutical Co., Ltd. announced new longer-term efficacy and safety data for Enspryng® [generic name: satralizumab ], a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody created by Chugai.

Faraday Pharmaceuticals, Inc., a biopharmaceutical company dedicated to improving the quality of life for patients experiencing potentially life-changing critical illness by focusing on muscle health, announced the enrollment of its first patient in a Phase 2 study of FDY-5301.

NRx Pharmaceuticals, announced the publication of peer-reviewed results from a prospective, open-label, administratively controlled trial of aviptadil for the treatment of respiratory failure in patients with Critical COVID-19.

Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced the grant to an employee of non-statutory stock options for the purchase of up to an aggregate of 4,000 shares of Yumanity’s common stock.

XORTX Therapeutics Inc., a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, announces its participation in the LD Micro Main Event, being held October 12 through 14, 2021.

ASLAN Pharmaceuticals, a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced the appointments of Dr Melinda Jennifer Gooderham, MSc MD FRCPC, Dr Jacob Thyssen, MD PhD DmSci, and Associate Professor Peter Foley, BMedSci MBBS MD FACD, as members of its Scientific Advisory Board.

HeartFlow, Inc., the leader in revolutionizing precision heart care, today announced the commencement of the REVEALPLAQUE (A pRospEctiVe, multicEnter study to AnaLyze PLAQUE using CCTA) trial to evaluate HeartFlow’s non-invasive plaque technology, an automated, deep learning-based method for identifying, characterizing and segmenting plaque in the coronary arteries.

Longeveron Inc. announced today that Geoff Green, Chief Executive Officer of Longeveron, will present at the Dawson James Small Cap Growth Conference on Thursday, October 21, 2021 at 11:25 a.m. ET in Jupiter, Florida.

VistaGen Therapeutics, Inc. (NASDAQ: VTGN), today announced the initiation of a Phase 2A clinical trial to evaluate the efficacy, safety and tolerability of PH94B as a potential treatment of anxiety in adults with Adjustment Disorder with Anxiety (AjDA).

Avid Bioservices, Inc. (NASDAQ:CDMO), today announced that the company is expanding its CDMO service offering into the rapidly growing cell and gene therapy market.